Oxaliplatin combined with S-1 capsule in the treatment of 62 cases with advanced gastric cancer

Objective： The aim of this study was to evaluate the efficacy and safety profile of DeFazio （S-l） combined with oxaliplatin against unresectable advanced or metastatic gastric cancer. Methods： Oxaliplatin was given intravenously at 130 mg/m2 for 2 h on dl and S-1 was administered bid. at 80 mg/m2/day on d1-14 followed by a 7-day rest during the 3-week schedule. Results： All 62 patients were assessed for efficacy and adverse events. The response and disease control rates were 47.3% and 80.8%, respectively. The median time to progression was 7.8 months, and the median overall survival was 11.6 months. The grade 3/4 adverse events were hematological toxicities, including neutropenia （11.3%）, thrombocytopenia （9.7%） and gastrointestinal reactions （6.5%）. Conclusion： The SOX regimen （oxaliplatin, 130 mg/m2 d l; S-1, 80 mg/m2/day, bid. d1-14, q3w） provide a favorable efficacy and safety profile in patients with advanced gastric cancer.

显微支撑喉镜下电刀切除会厌囊肿114例体会

目的探讨安全、有效的会厌囊肿切除术的手术技巧。方法用自制的单极电刀，凝、切、剥交替进行切除会厌囊肿114例，术后随访0．5～1年。结果在114例手术中，术野清淅，几乎无出血，除8例术中囊壁破裂外其余均完整切除，术后随访除5例失访外，均无囊肿复发，疗效满意。结论用自制的单极电刀切除会厌囊肿，确保了清淅的术野，以便能完整切除囊肿，降低了术后复发几率，值得临床推广。